Abstract
Mechanisms that control translation play important roles in tumor progression and metastasis. Emerging evidence has revealed that dysregulated translation also impacts immune evasion in response to cellular or oncogenic stress. Here, we summarize current knowledge regarding the translational control of immune checkpoints and implications for cancer immunotherapies.
Keywords:
PD-1/PD-L1; alternative translation initiation factors; immune checkpoints; integrated stress response (ISR) pathway; translation regulation.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Disease Progression
-
Eukaryotic Initiation Factors / metabolism
-
Gene Expression Regulation, Neoplastic / drug effects
-
Gene Expression Regulation, Neoplastic / immunology
-
Humans
-
Immune Checkpoint Inhibitors / pharmacology
-
Immune Checkpoint Inhibitors / therapeutic use*
-
Immune Checkpoint Proteins / genetics
-
Neoplasms / drug therapy
-
Neoplasms / genetics
-
Neoplasms / immunology*
-
Protein Biosynthesis / drug effects
-
Protein Biosynthesis / immunology*
-
Tumor Escape / drug effects
-
Tumor Escape / genetics*
Substances
-
Eukaryotic Initiation Factors
-
Immune Checkpoint Inhibitors
-
Immune Checkpoint Proteins